The Filing Desk

Cibus

CBUS · Nasdaq · Materials · Financials, fiscal 2016 to 2025

CBUS · Last close · November 19, 2026
$1.23
Value Cibus yourself

Cibus' revenue fell 14.6% to $4 million in fiscal 2025. Its operating margin was −2,680.1%, up from −6,062.8% a year earlier. Free cash flow was −$51 million. The diluted share count rose 97.0%.

Cibus, Inc. Latest fiscal year ended December 31, 2025 10-K filed March 17, 2026 · 0001628280-26-018815 Updated
Revenue
$4M
14.6%
Operating margin
−2,680.1%
3382.7 pts
Net income
−$127M
 
Free cash flow
−$51M
 
Return on capital
−169.5%
49.7 pts
Market cap
$95M
Nov 19 close
P/E
—
Loss: no P/E

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

About these figures. Share counts and per-share figures for earlier years are restated for a stock split (1-for-50), so every year is on today's share basis.

Charts show fiscal years, from the 10-K filings.

What Cibus does

Cibus is an agricultural biotechnology company. It uses gene editing, a way of making precise changes to a plant's DNA, to develop plant traits: built-in characteristics such as tolerance to weed killers or resistance to disease. Its process, which it calls the Rapid Trait Development System, is meant to let seed companies add these traits to their own best seed lines faster than traditional plant breeding.

Cibus plans to make money by licensing its traits to seed companies in exchange for royalties on the seed they sell. Its main program is rice that tolerates weed killers, aimed first at Latin America and the United States. It also works on ingredients such as lauric oils and fragrances made with yeast and fermentation, partly paid for by partners. It names large agricultural chemical companies, including BASF, Bayer Crop Science, Corteva and Syngenta, as its most likely competitors, along with smaller gene-editing firms; some competitors may also be customers.

Cibus has narrowed its work to save money. In 2025 it cut about 34 full-time jobs, and it cut another 15 in March 2026 while moving its core work to San Diego. At the end of 2025 it had 118 full-time employees. Cibus says there is substantial doubt about its ability to keep operating without raising more money soon.

Its biggest risks, as it describes them

  • Running out of money: it has lost money for years and needs new financing soon to keep operating.
  • Seed companies may not license its traits, or may not turn them into products farmers buy.
  • Its research and field trials may be slower than planned or may not work.
  • Rules for gene-edited crops differ by country and are still changing, and adverse changes could block its products.
  • Competition from large agricultural chemical companies with far more money and staff, and disputes over patents.
From Cibus's annual report on Form 10-K, filed March 17, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

Cibus lost money in fiscal 2025: a net loss of $127 million.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments144331410
Debt incl. finance leases180210
Net debt (negative means net cash)3−3−31−14−9
Net debt to EBITDA—————
Debt to equity1.3x0.0x0.0x0.0x0.0x
Interest coverage−20.5x−298.3x−2,592.5x−2,246.9x−1,234.5x
Current ratio3.1x2.5x1.6x0.8x0.7x
Quick ratio3.1x2.5x1.6x0.8x0.7x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project Cibus' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

What Cibus says to expect

  • Exit of 2026: annualized net cash usage run rateContinue to anticipate exiting 2026 at an annual net cash usage run-rate of approximately $35 million.
The company's own words, from its earnings release (Form 8-K, Exhibit 99), filed November 12, 2026. They are its expectations, not ours, and not a forecast or price target from The Filing Desk. Replaced when the next release is out.

Insider trades

No officer, director or 10% owner of Cibus reported buying or selling its shares on the open market between November 20, 2025 and November 19, 2026.

From Form 4 filings with the SEC. Grants, option exercises and shares withheld for tax aren't counted. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score2 of 83 of 83 of 8
Rule of 40−1,723.7%−1,246.3%−1,420.8%
Altman Z''−5.15−11.44−11.34
Accruals ratio−78.1%−43.2%−23.4%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailFailFail
Cash from operations is positiveFailFailFail
Return on assets roseFailPassPass
Cash from operations exceeds net incomePassPassPass
Debt fell relative to assetsFailPassFail
Current ratio roseFailFailFail
Share count didn't riseFailFailFail
Gross margin rose———
Revenue rose relative to assetsPassFailPass
F-score2 of 83 of 83 of 8
Companies that report no gross profit are scored on the other eight.

Compare

Put Cibus side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
CibusFY25−14.6%−2,680.1%−1,406.1%−169.5%—3
SenesTechFY2519.6%−292.9%−265.1%−389.3%—5Compare
Intrepid PotashFY2517.1%3.6%8.6%———Compare
American VanguardFY25−5.9%−5.5%−4.9%−6.2%—5Compare
LSB IndustriesFY2517.8%9.3%2.9%5.3%2.2x8Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

10 years of figures

Fiscal yearFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue000724260244
Revenue growth−68.6%27.3%−53.5%2,991.5%226.9%9.0%−99.4%1,057.3%134.6%−14.6%
Gross profit000−2−11−30———
Research and development6121012111112425044
Operating income−12−26−28−40−44−29−22−319−258−98
Net income−12−26−28−40−45−29−17−268−251−127
Diluted EPS (US$)−31.00−56.00−45.50−60.50−66.00−39.00−18.36−25.95−10.83−2.78
Diluted shares (millions)0011111102346
Cash flow
Cash from operations−9−13−20−32−44−19−19−46−58−51
Capital expenditure10123202411
Free cash flow−20−14−22−35−45−19−21−51−59−51
Dividends paid0000000000
Share buybacks0001000000
Acquisitions0000000000
Stock-based compensation1124952416118
Balance sheet at fiscal year end
Cash and short-term investments557956030144331410
Debt incl. finance leases————20180210
Total assets177211988633722544350305
Total liabilities4152526262315206252283
Shareholders' equity13589362371472949222
Margins and ratios
Gross margin49.9%100.0%100.0%−27.2%−47.3%−9.9%100.0%———
Operating margin−3,034.8%−5,076.6%−11,913.1%−543.8%−183.8%−112.9%−14,248.4%−17,550.0%−6,062.8%−2,680.1%
Net margin−3,029.1%−5,114.2%−11,820.8%−542.9%−188.0%−112.4%−10,758.6%−14,729.1%−5,898.4%−3,492.3%
Free cash flow margin−4,927.6%−2,670.1%−9,342.8%−478.6%−190.6%−74.3%−13,301.9%−2,781.0%−1,380.8%−1,406.1%
Rule of 40 (growth + FCF margin)−4,996.2%−2,642.8%−9,396.3%2,512.9%36.3%−65.3%−13,401.3%−1,723.7%−1,246.3%−1,420.8%
Return on capital—————−104.8%−165.2%−189.2%−119.8%−169.5%
Return on equity—−73.6%−37.0%−50.8%−90.2%−114.5%−158.1%−178.0%−130.4%−223.0%
Return on assets—−58.5%−29.2%−38.3%−59.2%−58.1%−56.7%−94.4%−56.2%−38.8%
Net debt to EBITDA——————————
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Cibus' Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Cibus.